These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36623857)

  • 1. Extended-release monthly buprenorphine injection.
    Cuperfain AB; Costa T; Chopra N
    CMAJ; 2023 Jan; 195(1):E14. PubMed ID: 36623857
    [No Abstract]   [Full Text] [Related]  

  • 2. Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges.
    Arunogiri S; Lintzeris N
    J Subst Abuse Treat; 2021 May; 124():108221. PubMed ID: 33303254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute Pain Management for a Tibial Plateau Fracture Shortly After a Buprenorphine XR Depot Injection: A Case Report.
    Sivanathan L; Logan E; Popovski K; Goel A; Hauck T; Ladha KS
    J Addict Med; 2022 Sep-Oct 01; 16(5):599-601. PubMed ID: 35093985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Availability of Extended-Release Buprenorphine to Treat Opioid Use Disorders Among Medicaid-Covered Patients.
    Shover CL
    Psychiatr Serv; 2021 Feb; 72(2):225-226. PubMed ID: 32907476
    [No Abstract]   [Full Text] [Related]  

  • 7. Is buprenorphine-naloxone ready for prime time in the treatment of opioid addiction in managed care?
    Curtiss FR
    J Manag Care Pharm; 2008 Mar; 14(2):195-7. PubMed ID: 18331121
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 9. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
    Sigmon SC; Bigelow GE
    Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
    [No Abstract]   [Full Text] [Related]  

  • 10. Using Extended Release Buprenorphine Injection to Discontinue Sublingual Buprenorphine: A Case Series.
    Ritvo AD; Calcaterra SL; Ritvo JI
    J Addict Med; 2021 May-Jun 01; 15(3):252-254. PubMed ID: 32925232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative Management of Extended-release Buprenorphine.
    Hickey TR; Henry JT; Edens EL; Gordon AJ; Acampora G
    J Addict Med; 2023 Jan-Feb 01; 17(1):e67-e71. PubMed ID: 35862898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tramadol dependence: treatment with buprenorphine/naloxone.
    Ritvo JI; Koonce R; Thurstone CC; Causey HL
    Am J Addict; 2007; 16(1):67-8. PubMed ID: 17364425
    [No Abstract]   [Full Text] [Related]  

  • 13. Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder.
    Shi Z; Li X; Kampman KM; Childress AR; Wiers CE; Langleben DD
    J Clin Psychiatry; 2023 Apr; 84(3):. PubMed ID: 37074295
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnosis and Treatment of Opioid Use Disorder in 2020.
    Wakeman SE
    JAMA; 2020 May; 323(20):2082-2083. PubMed ID: 32329798
    [No Abstract]   [Full Text] [Related]  

  • 15. Buprenorphine Maintenance vs. Placebo for Opioid Dependence.
    Raleigh MF
    Am Fam Physician; 2017 Mar; 95(5):Online. PubMed ID: 28290640
    [No Abstract]   [Full Text] [Related]  

  • 16. Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
    Shulman M; Choo TH; Scodes J; Pavlicova M; Wai J; Haenlein P; Tofighi B; Campbell ANC; Lee JD; Rotrosen J; Nunes EV
    J Subst Abuse Treat; 2021 May; 124():108292. PubMed ID: 33771287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update.
    Soyka M
    Pharmacopsychiatry; 2021 Jan; 54(1):18-22. PubMed ID: 33212514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New slow-release buprenorphine formulations for optimization of opioid substitution].
    Soyka M; Pogarell O
    Nervenarzt; 2019 Sep; 90(9):932-937. PubMed ID: 31399813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine for opioid dependence.
    Milne M; Crouch BI; Caravati EM
    J Pain Palliat Care Pharmacother; 2009; 23(2):153-5. PubMed ID: 19492216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
    Mannelli P; Wu LT; Peindl KS; Swartz MS; Woody GE
    Drug Alcohol Depend; 2014 May; 138():83-8. PubMed ID: 24602363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.